Outcomes of Impella 5.0 and 5.5 for cardiogenic shock: A single‐center 137 patient experience
Artificial Organs · 2024
DOI: 10.1111/aor.14735 ↗Kurz gefasst
Fachartikel in der Zeitschrift Artificial Organs, 2024. Verfasst von Yeahwa Hong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Pittsburgh Medical Center Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Shock, Cardiogenic, Heart-Assist Devices, Hospital Mortality. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, Thoracic Surgery Foundation, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Background
This study evaluated the outcomes of patients with cardiogenic shock (CS) supported with Impella 5.0 or 5.5 and identified risk factors for in‐hospital mortality.
Methods
Adults with CS who were supported with Impella 5.0 or 5.5 at a single institution were included. Patients were stratified into three groups according to their CS etiology: (1) acute myocardial infarction (AMI), (2) acute decompensated heart failure (ADHF), and (3) postcardiotomy (PC). The primary outcome was survival, and secondary outcomes included adverse events during Impella support and length of stay. Multivariable logistic regression was performed to identify risk factors for in‐hospital mortality.
Results
One hundred and thirty‐seven patients with CS secondary to AMI ( n = 47), ADHF ( n = 86), and PC ( n = 4) were included. The ADHF group had the highest survival rates at all time points. Acute kidney injury (AKI) was the most common complication during Impella support in all 3 groups. Increased rates of AKI and de novo renal replacement therapy were observed in the PC group, and the AMI group experienced a higher incidence of bleeding requiring transfusion. Multivariable analysis demonstrated diabetes mellitus, elevated pre‐insertion serum lactate, and elevated pre‐insertion serum creatinine were independent predictors of in‐hospital mortality, but the etiology of CS did not impact mortality.
Conclusions
This study demonstrates that Impella 5.0 and 5.5 provide effective mechanical support for patients with CS with favorable outcomes, with nearly two‐thirds of patients alive at 180 days. Diabetes, elevated pre‐insertion serum lactate, and elevated pre‐insertion serum creatinine are strong risk factors for in‐hospital mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, University of Pittsburgh Medical Center Pittsburgh, Pittsburgh, Pennsylvania, USA.
- School of Medicine, University of Pittsburgh Medical Center Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Division of Cardiology, University of Pittsburgh Medical Center Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Critical Care Medicine, University of Pittsburgh Medical Center Pittsburgh, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Yeahwa Hong
Förderung
- NHLBI NIH HHS
- Thoracic Surgery Foundation
- National Heart, Lung, and Blood Institute
Zitieren
APA
Hong, Y., Agrawal, N., Hess, N. R., Ziegler, L. A., Sicke, M. M., Hickey, G. W., Ramanan, R., Fowler, J. A., Chu, D., Yoon, P. D., Bonatti, J. O., & Kaczorowski, D. J. (2024). Outcomes of Impella 5.0 and 5.5 for cardiogenic shock: A single‐center 137 patient experience. Artificial Organs. https://doi.org/10.1111/aor.14735
Vancouver
Hong Y, Agrawal N, Hess NR, Ziegler LA, Sicke MM, Hickey GW, et al. Outcomes of Impella 5.0 and 5.5 for cardiogenic shock: A single‐center 137 patient experience. Artificial Organs. 2024. doi:10.1111/aor.14735
BibTeX
@article{Hong2024,
author = {Hong, Yeahwa and Agrawal, Nishant and Hess, Nicholas R and Ziegler, Luke A and Sicke, McKenzie M and Hickey, Gavin W and Ramanan, Raj and Fowler, Jeffrey A and Chu, Danny and Yoon, Pyongsoo D and Bonatti, Johannes O and Kaczorowski, David J},
title = {Outcomes of Impella 5.0 and 5.5 for cardiogenic shock: A single‐center 137 patient experience},
journal = {Artificial Organs},
year = {2024},
doi = {10.1111/aor.14735}
}
EUVIMED